Jagsonpal Pharma Q2 FY27 Earnings Call — Analysis (NSE: JAGSNPHARM)
Jagsonpal reported Q2 consolidated revenue of ₹96 Cr (+29% YoY) driven by the Aequitas consolidation, while reiterating its target to cross ₹100 Cr quarterly run-rate in Q3 and achieve ₹500 Cr revenue by FY28.
Result quality: stable — Steady quarter. Management sentiment: optimistic.
The take
Q2FY27 Consolidated Revenue ₹96 Cr ( +29% YoY ) . New guidance — FY28 jpl consolidated revenue ₹500 Cr . New story: Organic growth re-acceleration .
Results
Consolidated revenue stood at ₹96 Cr (+29% YoY) with EBITDA margin at 19.3% and PAT of ₹12 Cr; standalone revenue grew 9.3% YoY to ₹81 Cr with EBITDA margin of 22.7% and PAT of ₹13 Cr.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Consolidated Revenue | ₹96 Cr | +29% | yoy · Q2FY27 |
| Standalone Revenue | ₹81 Cr | +9.3% | yoy · Q2FY27 |
| Consolidated Revenue H1 | ₹179 Cr | none · H1FY27 | |
| Standalone Revenue H1 | ₹164 Cr | none · H1FY27 | |
| Standalone Gross Margin | 64.1% | none · Q2FY27 | |
| Standalone Gross Margin H1 | 64.7% | +70bps | yoy · H1FY27 |
| Standalone EBITDA Margin | 22.7% | none · Q2FY27 · broadly stable | |
| Consolidated EBITDA Margin | 19.3% | none · Q2FY27 | |
| H1 EBITDA Margin | 22.9% | +40bps | yoy · H1FY27 |
| Consolidated PAT | ₹12 Cr | none · Q2FY27 · 12.8% margin | |
| Standalone PAT | ₹13 Cr | none · Q2FY27 · 15.5% margin | |
| Cash and Bank Balance | ₹135 Cr | point_in_time · Q2FY27 · Sep-26 | |
| Consolidated Operating Cash Flow | ₹25 Cr | none · H1FY27 |
Guidance
Management expects quarterly revenue to cross ₹100 Cr in Q3FY27 with consolidated EBITDA margins returning to ~22%, aiming for ₹500 Cr organic revenue by FY28.
What management committed to
- Jagsonpal will achieve consolidated revenue of ₹500 crores by FY2028. — ₹500 crores, FY28
- Jagsonpal's quarterly standalone revenue will exceed ₹100 crores in Q3 FY27. — > ₹100 crores, Q3 FY27
- JPL consolidated EBITDA margin will exceed 22% in Q3 FY27. — > 22%, Q3 FY27
- The first value-added brand from the Aequitas portfolio will be launched by end of November 2026. — November 2026
- [Aequitas Healthcare] will reach revenue of ₹100 crores by FY28. — ₹100 crores, FY28
Key themes
Inorganic scaling and core brand acceleration
How the narrative shifted
- Organic growth re-acceleration: Prior 'green shoots' narrative was replaced by a 'bolder Jagsonpal' framing, acknowledging the recent performance gap and spinning the quarter as a launchpad rather than a proof point.
- Aequitas hospital entry and synergy: The call provides tangible integration milestones lacking in the prior call, including a specific product launch date and a faster revenue target.
- Operational productivity and margin expansion: Vague prior talk of '240bps improvement' is sharpened into a binding quarterly guidance of >22% consolidated, supported by strong standalone margin discipline.
- Disciplined capital allocation and buyback: Cash balance of ₹135 Cr is consistently cited as the foundation for executing the dual acquisition strategy without leverage, providing optionality for further 'fast tracking' of the mission.
- Favourable domestic pharma demand backdrop: IPM growth remains a reference point, but management pushes back on using Pharmarack secondary data as a direct proxy for their own revenue performance, framing it as a loose guide rather than a tight benchmark.
- Brand premiumization and scientific promotion: The prior call's generic 'premium is already showing up' is now tied to a specific multi-year improvement trajectory, with the consolidated drag isolated and explained.
- Mission ₹500 Cr scale ambition: This concrete, quantified goal did not exist in the prior call's narrative, replacing the earlier thematic focus on 'organic re-acceleration' and '1.5x leverage' with a definitive revenue number.
- API price pressure / input cost inflation: New macro narrative not present in the prior call; introduced in the Q&A to externalize a key source of margin dilution from Aequitas.
Operational commentary
- Completed acquisition of controlling stake in Aequitas Healthcare (July 2026), providing direct entry to corporate hospital chains and critical care segments.
- Completed acquisition of Group Pharma Wellness portfolio (effective October 1, 2026), adding 2 established brands in hematinics and respiratory, 10,000 unique doctors, and expansion into MP, UP, and Karnataka.
- Power brands showed strong momentum: Maintane (+29% vs market +20%), Endoreg (+20% vs market degrowth), Metadec (+14%), and Lycored (+15%).
- Top 10 brands represent ~58% of revenue, with 9 brands ranked in the top 5 in their respective molecule markets.
- Doctor reach expanded to ~1,37,000 doctors with MR productivity up ~10% following field force restructuring and compensation alignment.
Analyst Q&A
Q. Feasibility of reaching ₹500 Cr revenue by FY28 organically given current ~10% growth rate.
Management stated that recent investments in sales force productivity, new product introductions, and full integration of acquisitions will accelerate growth to >1.5x IPM without needing further M&A.
Q. Discrepancy between Pharmarack secondary sales data (12-16.8%) and reported standalone primary growth (~9.3%).
Management explained that secondary sampling data inherently carries discrepancies, but branded prescription is growing in double digits and primary revenue will converge closer to market data over coming quarters.
Q. Whether standalone reporting will separately show organic growth vs Group Pharma acquisition in Q3.
Management committed to providing commentary splits between organic core states and geographic expansion in the 6 non-core states.
Q. Long-term stance on owning manufacturing / API backend for export markets.
Management noted that while the current 2-year model remains asset-light domestic formulation, owning backend assets will be evaluated with promoters if entering international markets over a 5-year horizon.
Research and educational content only. Not investment advice.